GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (FRA:VE11) » Definitions » Price-to-Tangible-Book

Aravive (FRA:VE11) Price-to-Tangible-Book : 1.48 (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aravive Price-to-Tangible-Book?

As of today (2024-04-30), Aravive's share price is €0.0325. Aravive's Tangible Book per Share of Sep. 2023 for the quarter that ended in Sep. 2023 was €0.02. Hence, Aravive's Price to Tangible Book Ratio of today is 1.48.

The historical rank and industry rank for Aravive's Price-to-Tangible-Book or its related term are showing as below:

FRA:VE11' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.67   Med: 1.93   Max: 7.42
Current: 1.63

During the past 11 years, Aravive's highest Price to Tangible Book Ratio was 7.42. The lowest was 0.67. And the median was 1.93.

FRA:VE11's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.65 vs FRA:VE11: 1.63

A closely related ratio is called PB Ratio. As of today, Aravive's share price is €0.0325. Aravive's Book Value per Sharefor the quarter that ended in Sep. 2023 was €0.02. Hence, Aravive's P/B Ratio of today is 1.48.


Aravive Price-to-Tangible-Book Historical Data

The historical data trend for Aravive's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Price-to-Tangible-Book Chart

Aravive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 3.03 1.96 1.11 6.90

Aravive Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.78 6.90 - - 5.55

Competitive Comparison of Aravive's Price-to-Tangible-Book

For the Biotechnology subindustry, Aravive's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aravive's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aravive's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Aravive's Price-to-Tangible-Book falls into.



Aravive Price-to-Tangible-Book Calculation

Aravive's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2023 )
=0.0325/0.022
=1.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Aravive Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Aravive's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Aravive (FRA:VE11) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (FRA:VE11) Headlines

No Headlines